About

Provided by Mintz

Mintz’s team of industry-dedicated attorneys helps entrepreneurs launch and protect great ideas, facilitates funding opportunities, works with leading industry investors and underwriters in innovative financings and offerings, represents strategics, private equity firms, venture-backed businesses and entrepreneurs in buy- and sell-side M&A transactions, and counsels emerging as well as established and public companies in all aspects of their businesses, including intellectual property matters and regulatory approvals and compliance.

    • Intellectual Property practice of more than 130 professionals who represent clients in prosecution, strategy, business transactions, and litigation – more than 40 of whom have PhDs;
    • $80B+ in transactions since 2020, including public offerings, joint ventures, licensing and complex collaborations, mergers and acquisitions, divestitures, distribution deals, and private financings;
    • National reputation as go-to firm for high-stakes life sciences litigation, with an exemplary record in resolving disputes with collaboration/licensing partners and representing corporate officers and directors of life sciences companies in disputes; and
    • Regulatory and compliance advice spanning FDA strategy and interactions, clinical trials, fraud and abuse, compliance program development, HIPAA, marketing and advertising, drug pricing and reimbursement, supply and distribution agreements.

Chambers Review

Provided by Chambers

Life Sciences - USA - Nationwide

4
Band 4

What the Team is Known For

Mintz has an extensive practice advising companies on a wealth of transactional matters in the life sciences sector. The team at Mintz is well equipped to provide support and guidance relating to M&A, private equity financings, initial public offerings, collaboration and licensing agreements, business combinations and SPAC deals.

Key contact

William Hicks is a key contact.

Work Highlights

  • Mintz represented ArriVent BioPharma, Inc. in its $175 million initial public offering underwritten by Goldman Sachs, Jefferies and Citigroup.

Strengths

Provided by Chambers

Clients

Provided by Mintz

Amgen

ArriVent BioPharma

BeiGene, Ltd.

F-Star Therapeutics

Fulgent Genetics

Leerink

Pieris Pharmaceuticals, Inc.

QIAGEN N.V.

Standard BioTools